Spy II Clinical Registry
A Clinical Registry to Assess Performance and Clinical Utility of the SpyGlass Direct Visualization System
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Brussels, Belgium, 1070
- Erasme Hospital - Belgium
-
-
-
-
-
Kobenhavn NV, Denmark, 2400
- Bispebjerg Hospital, Denmark
-
-
-
-
-
Lyon, Cedex 03, France, 69437
- Hôpital Edouard Herriot
-
-
-
-
-
Dusseldorf, Germany, D-40217
- Evangelisches Krankenhaus Düsseldorf
-
-
-
-
-
Roma, Italy, 00161
- Policlinico Agostino Gemelli
-
-
-
-
California
-
San Francisco, California, United States, 94120
- California Pacific Medical Center
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- University Of Colorado Hospital
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202-5253
- Indiana University Medical Center
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Beth Israel Deaconess Medical Center
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905-0001
- Mayo Clinic
-
-
New York
-
New York, New York, United States, 10032
- Columbia University Medical Center
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- Cleveland Clinic Foundation
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19111
- Fox Chase Cancer Center
-
Pittsburgh, Pennsylvania, United States, 15123
- University of Pittsburgh
-
-
South Carolina
-
Charleston, South Carolina, United States, 29425-0001
- Medical University of South Carolina
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Male or female >= 18 years of age
- Willing and able to comply with the Registry procedures and provide written informed consent to participate in the Registry
- Indicated for ERCP or ERCP/cholangioscopy (with or without biopsy)
Exclusion Criteria:
- Subjects for whom endoscopic procedure are medically contraindicated
- Subjects for whom ERCP are medically contraindicated
- Subjects for whom medical condition warrants use of device outside of indication for use
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Arm 1
Test of SpyGlass device
|
The SpyGlass Direct Visualization System is an integrated product platform that is designed to provide a direct intraluminal view of the biliary duct system and direct therapeutic devices.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Procedural Success as Defined by: 1. Ability to Visualize Stricture & Obtain Biopsy of Lesion Adequate for Histological Examination in Suspected Malignancy Cases or 2. Ability to Visualize Stone(s) & Successfully Initiate Stone Fragmentation & Removal.
Time Frame: During Procedure
|
During Procedure
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Joyce Peetermans, PhD, Boston Scientific Corporation
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- E7012
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.